Safety and immunogenicity of a booster dose of 7-valent pneumococcal
conjugate vaccine (PCV7) were evaluated in 29 patients with idiopathic
nephrotic syndrome (INS), who had been primed 12 months earlier with one
dose of PCV7. PCV7 was not associated with increased risk of INS relapse
(RR = 0.77, p = 0.8) and serotype-specific antibodies increased in all
subjects at 1 month (p < 0.01). The quantitative characteristics of
immune response and the effect of treatment with mycophenolate mofetil
and/or cyclosporine A following booster PCV7 were similar with primary
response. Additional PCV7 doses could be safely given in children with
INS to increase circulating antibodies above the protective threshold.
(C) 2014 Elsevier Ltd. All rights reserved
